Blood cells are targeted for destruction by antibodies in many clinically important disorders. Some of these conditions have an autoimmune etiology; others are caused by alloantibodies, isoantibodies or drug sensitivity. We engaged in studies to improve the understanding of this family of disorders.
Method of detecting heparin-induced thrombocytopenia. US Patent 5,972,718 Issued October 26, 1999
Method and kit for detecting heparin-induced thrombocytopenia. US Patent 5,972,717 Issued October 26, 1999
Nucleic acids for the detection of the Bak polymorphism in human platelet membrane glycoprotein IIb US Patent 5,652,357 Issued July 19, 1997
Polymorphism of human platelet membrane glycoprotein IIIa and diagnostic and therapeutic applications thereof 5,091,302 Issued February 25, 1992; US Patent 5,391,714 Patent Issued February 21, 1995; US Patent 5,670,337 Issued September 23, 1997; Japanese Patent 3,221,679 Issued August 17, 2001
A method of detecting platelet-activating antibodies in patients suspected of having heparin-induced thrombocytopenia. Patent 14/437,066 issued December 26, 2017
Research articles that explore Versiti Blood Research Institute investigators and their expertise in blood health innovation.
Investigator Laboratory Sites
Learn more about the amazing research, lab team, and contact information for some of our investigators.
Join Versiti Blood Research Institute
Versiti Blood Research Institute, located in Milwaukee, Wisconsin, includes basic and clinical researchers in a variety of blood health fields.
Our Investigators
Browse our Investigators, Emeritus Investigators, and other members of the Blood Research Institute.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking ACCEPT, you consent to the use of all the cookies.